Generic Name and Formulations:
Succimer 100mg; caps.
Recordati Rare Diseases, Inc.
Indications for CHEMET:
Lead poisoning in children with blood lead levels >45micrograms/dL.
May swallow caps whole or put contents onto a small amount of soft food or a spoon and swallow, followed by fruit drink. <12months: not recommended. ≥12months: initially 10mg/kg (or 350mg/m2) every 8 hours for 5 days, then reduce frequency to every 12 hours for 14 more days. Allow at least 14 days between courses unless blood lead levels indicate need for more prompt treatment. Treatment for more than 3 consecutive weeks: not recommended.
Monitor for rebound elevated lead levels by measuring blood levels at least once weekly. Maintain adequate hydration. Monitor renal and hepatic function. Monitor for neutropenia; instruct patients to report any sign of infection or rash. Renal impairment. History of hepatic dysfunction. Find and remove source of lead from environment. Pregnancy (Cat.C). Nursing mothers: not recommended.
Other concomitant chelation therapy (e.g., EDTA): not recommended. False (+) results with nitroprusside test (e.g., Ketostix).
GI upset, elevated serum transaminases, rash, pain, cramps, flu-like symptoms, dizziness, drowsiness, paresthesia; neutropenia, mucocutaneous vesicular eruptions (rare).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib